Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q1 2025 Earnings Presentation
24 slides from Nykode Therapeutics Asa's earnings presentation, May 28, 2025
Slide 1: Q1 2025 Results Presentation
Q1 2025 Results Presentation May 28, 2025
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode
Today’s presenters from Nykode MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN Chief Executive Officer Chief Scientific Officer & Chief Financial Officer Business Development Nykode Therapeutics | Q1 '25 webcast | Non-confidential 3
Slide 4: Latest Corporate Developments
Latest Corporate Developments • Finalized organizational streamlining in the first quarter of 2025 and continued strong focus on cost control. • Elected Susanne Stuffers as Chair of the Board at the Extraordinary General Meeting on April 23, 2025. • Cash dividend of NOK 1.00 per share approved at SU
Slide 5: Recent Achievements
Recent Achievements • Published final Phase 2 data from the VB-C-02 trial in the peer-reviewed BMJ Journal for ImmunoTherapy of Cancer, confirming the prolonged benefit and definitive vaccination effect observed in the interim analysis. • Presented new preclinical data demonstrating Nykode’s APC-tar
Slide 6: VB10.16 in HPV16+ cancers
VB10.16 in HPV16+ cancers Nykode Therapeutics | Q1 '25 webcast | Non-confidential 6
Slide 7: BMJ Journal for ImmunoTherapy of Cancer
BMJ Journal for ImmunoTherapy of Cancer Highlights • Favorable safety profile for VB10.16 + atezolizumab in 52 patients • Confirmed durable efficacy, with mOS of 24.7 months and ORR up to 29% in PD-L1+ subgroup • Prolonged benefit and vaccination effect affirmed Nykode Therapeutics | Q1 '25 webcast
Slide 8: ASCO 2025: VB-C-02 Trial Highlights
ASCO 2025: VB-C-02 Trial Highlights • VB10.16 combined with atezolizumab induced durable clinical responses in HPV16+ cervical cancer. • Stronger HPV16-specific T cell responses were associated with reduced systemic immunosuppression during treatment. • Tumor microenvironment (TME) characteristics a
Slide 9: VB-C-03 trial on track
VB-C-03 trial on track Combination treatment of VB10.16 + pembrolizumab in 1L HPV16+, PD-L1+ R/M HNSCC Phase 1 Dose escalation phase (BOIN escalation decision algorithm) • Accrual for highest dose (9 mg) completed 9 mg 9m g 9 mg (treatment-ongoing). RP2D* analysis 9 mg 9 mg 9 mg • Safety data (ident
Slide 10: VB10.NEO- Individualized cancer immunotherapy
VB10.NEO- Individualized cancer immunotherapy Nykode Therapeutics | Q1 '25 webcast | Non-confidential 10
Slide 11: ASCO 2025: VB-N-02 Trial Highlights
ASCO 2025: VB-N-02 Trial Highlights • VB10.NEO is a personalized, DNA-based neoantigen vaccine evaluated in combination with atezolizumab in an open-label, dose-escalation, multicenter Phase 1b trial. • Trial included heavily pre-treated patients, with a medium of 5 prior lines of therapy, across >1
Slide 12: Immune Tolerance
Immune Tolerance Nykode Therapeutics | Q1 '25 webcast | Non-confidential 12
Slide 13: Immune Tolerance – Nykode's APC targeted platform
Immune Tolerance – Nykode’s APC targeted platform uniquely positioned to target antigens to tolerizing DCs OPPORTUNITY AND UNMET NEED NEW PROGRESS ▪ Opportunities within autoimmune diseases, ▪ Successful establishment of several Tolerance- allergies and organ transplant rejection relevant methods an
Slide 14: Long, durable efficacy observed after starting treatment post disease onset
Long, durable efficacy observed also after starting treatment post disease onset LATER THERAPEUTIC TREATMENT Target 2 Targeted 4 MOG vaccine 2 (27-63) PBS ✱ EAE score (0-8) Targeted 200 3 vaccine 2 160 AUC (5-35) 2 120 Daily clinical scores (5-60) 80 1 Score >/= 1 40 & 3 days later Ongoing 0 0 until
Slide 15: New method enabling analysis of the regulatory T cells
New method enabling analysis of the regulatory T cells Set up to further improve and select the optimal version of the platform STRONG INDUCTION OF AG-SPECIFIC REGULATORY T CELLS Proliferation Foxp3+ Treg cells Day 4 (after 1x injection) Day 7 % Foxp3+ of CD4+Thy1.2+ cells % Ki67+ of CD4+Thy1.2+ cel
Slide 16: First proof of Nykode's treatment reducing auto-antibodies
First proof of Nykode’s treatment reducing auto-antibodies REDUCTION OF AUTOANTIBODIES • Auto-antibodies anti-MOG (35-55) IgG play an important role in immune ✱✱✱ diseases MOG-specific IgG (µg/mL) MOG 100 (27-63) • Treatment induced Targeted 80 reduction of Vaccine 1 60 Antigen-specific IgG auto- 40
Slide 17: Organizational Priorities
Organizational Priorities Nykode Therapeutics | Q1 '25 webcast | Non-confidential 17
Slide 18: 2025 Organizational Priorities
2025 Organizational Priorities VB10.16 VB10.NEO Immune Tolerance • Present new C-02 clinical data at • Present new N-02 clinical data at ASCO 2025 • Present additional data on the ASCO 2025 path to optimize the immune • Advance C-03 trial execution as • Update strategic approach to tolerance platfo
Slide 19: Q1 2025 Financial Results
Q1 2025 Financial Results
Slide 20: Streamlined Operations and Cost Discipline
Streamlined Operations and Cost Discipline Finalized organizational streamlining in Q1 2025 Lean and focused organization Continued emphasis on cost control and strategic prioritization Full effect of restructuring expected by Q3 2025 Updated cash runway guidance to be provided as part of
Slide 21: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 Q1 2025 Q1 2024 FY 2024 • Decrease in Q1 2025 mainly due to termination of Revenue from contracts with customers - 827 8,679 agreement with Genentech in Q4 2024 Other income 137 189 479 Other income Total revenue and other in
Slide 22: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 31/03/2025 31/12/2024 • Cash position of $106.2m at March 31, 2025 ASSETS Non-current assets Other non-current receivables Property, plant and equipment 3,585 3,741 • Mainly reflects the NOK 325 million payment to the Right-of-use assets 3,
Slide 23: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 31/03/2025 31/12/2024 Equity EQUITY AND LIABILITIES • Total equity of $134m as per March 31, 2025 Equity Share capital 367 367 • Equity ratio of 91% Share premium 128,986 128,986 Other capital reserves 18,067 18,683 Other components of equity (3,086) (3,060
Slide 24: Unlocking the Future of Medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | Q1 '25 webcast | Non-confidential
Nykode Therapeutics As — Q1 2025 Earnings Presentation on 6ix